Xiangxue Pharmaceutical (300147) — Tangible Net Worth Ratio
Xiangxue Pharmaceutical (300147) has a Tangible Net Worth Ratio of -2128.5% as of December 2025. This metric is calculated by deducting intangible assets (CN¥979.34 Million) from net assets (CN¥43.95 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See 300147 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Xiangxue Pharmaceutical Tangible Net Worth Ratio (2007–2025)
This chart shows how Xiangxue Pharmaceutical's Tangible Net Worth Ratio has changed across 19 annual periods from 2007 to 2025. As of December 2025, the ratio stands at -2128.5%, reflecting net assets of CN¥43.95 Million with intangible assets of CN¥979.34 Million CNY. See Xiangxue Pharmaceutical defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Xiangxue Pharmaceutical (2007–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Xiangxue Pharmaceutical from 2007 to 2025, covering 19 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Xiangxue Pharmaceutical market capitalisation.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -2128.5% | CN¥43.95 Million | CN¥979.34 Million | CN¥6.75 Billion | ▼ -2154.9 pp |
| 2024 | 26.3% | CN¥1.44 Billion | CN¥1.06 Billion | CN¥7.50 Billion | ▼ -15.1 pp |
| 2023 | 41.4% | CN¥2.31 Billion | CN¥1.36 Billion | CN¥8.28 Billion | ▼ -10.1 pp |
| 2022 | 51.5% | CN¥2.82 Billion | CN¥1.37 Billion | CN¥9.35 Billion | ▼ -10.5 pp |
| 2021 | 62.0% | CN¥3.76 Billion | CN¥1.43 Billion | CN¥11.38 Billion | ▼ -15.1 pp |
| 2020 | 77.1% | CN¥4.25 Billion | CN¥973.96 Million | CN¥9.78 Billion | ▼ -5.3 pp |
| 2019 | 82.4% | CN¥4.11 Billion | CN¥721.63 Million | CN¥8.46 Billion | ▲ +1.8 pp |
| 2018 | 80.6% | CN¥4.01 Billion | CN¥778.35 Million | CN¥8.63 Billion | ▼ -5.0 pp |
| 2017 | 85.6% | CN¥3.88 Billion | CN¥559.82 Million | CN¥9.44 Billion | ▼ -3.5 pp |
| 2016 | 89.1% | CN¥3.68 Billion | CN¥401.17 Million | CN¥7.99 Billion | ▼ -2.4 pp |
| 2015 | 91.5% | CN¥3.55 Billion | CN¥301.95 Million | CN¥4.65 Billion | ▲ +4.2 pp |
| 2014 | 87.3% | CN¥1.87 Billion | CN¥238.01 Million | CN¥3.59 Billion | ▲ +0.1 pp |
| 2013 | 87.2% | CN¥1.71 Billion | CN¥219.59 Million | CN¥3.47 Billion | ▼ -2.6 pp |
| 2012 | 89.7% | CN¥1.54 Billion | CN¥157.82 Million | CN¥2.95 Billion | ▼ -2.2 pp |
| 2011 | 92.0% | CN¥1.42 Billion | CN¥113.96 Million | CN¥1.92 Billion | ▼ -3.1 pp |
| 2010 | 95.1% | CN¥1.37 Billion | CN¥67.38 Million | CN¥1.85 Billion | ▲ +15.9 pp |
| 2009 | 79.2% | CN¥337.62 Million | CN¥70.28 Million | CN¥698.31 Million | ▲ +16.4 pp |
| 2008 | 62.8% | CN¥196.54 Million | CN¥73.15 Million | CN¥551.47 Million | ▼ -12.6 pp |
| 2007 | 75.4% | CN¥191.45 Million | CN¥47.07 Million | CN¥553.43 Million | — |